The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Research

• Publication date

  2018-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-17-3139PMID 29339539
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Yorkie Regulates Neurodegeneration Through Canonical Pathway and Innate Immune Response

  2018cited by this paper
• PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity

  2017cited by this paper
• Single tumor-initiating cells evade immune clearance by recruiting type II macrophages

  2017cited by this paper
• PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.

  2017cited by this paper
• Epicardial YAP/TAZ orchestrate an immunosuppressive response following myocardial infarction

  2017cited by this paper
• Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses

  2017cited by this paper
• Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells

  2017cited by this paper
• The Hippo Pathway: A Master Regulatory Network Important in Development and Dysregulated in Disease.

  2017cited by this paper
• The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer

  2017cited by this paper
• Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients

  2017cited by this paper
• Rottlerin exhibits antitumor activity via down-regulation of TAZ in non-small cell lung cancer

  2016cited by this paper
• Yes-Associated Protein Mediates Immune Reprogramming in Pancreatic Ductal Adenocarcinoma

  2016cited by this paper
• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

  2016cited by this paper
• Mechanisms of Hippo pathway regulation

  2016cited by this paper
• YAP/TAZ at the Roots of Cancer.

  2016cited by this paper
• Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis

  2016cited by this paper
• Regulation of PD-L1: a novel role of pro-survival signalling in cancer.

  2016cited by this paper
• Hippo/MST1 signaling mediates microglial activation following acute cerebral ischemia-reperfusion injury.

  2016cited by this paper
• Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial

  2016cited by this paper
• The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity.

  2016cited by this paper
• Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers

  2015cited by this paper
• Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer.

  2015cited by this paper
• Opposing roles of conventional and novel PKC isoforms in Hippo-YAP pathway regulation

  2015cited by this paper
• Targeting YAP-dependent MDSC infiltration impairs tumor progression

  2015cited by this paper
• Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

  2015cited by this paper
• PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

  2014cited by this paper
• Improved vectors and genome-wide libraries for CRISPR screening

  2014cited by this paper
• TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells

  2014cited by this paper
• A comparative encyclopedia of DNA elements in the mouse genome

  2014cited by this paper
• PD-L1 Expression in Triple-Negative Breast Cancer

  2014cited by this paper
• Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

  2014cited by this paper
• Conservation and divergence in the transcriptional programs of the human and mouse immune systems

  2013cited by this paper
• Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation.

  2013cited by this paper
• Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1

  2013cited by this paper
• Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling.

  2012cited by this paper
• Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF.

  2011cited by this paper
• TAZ is a novel oncogene in non-small cell lung cancer

  2011cited by this paper
• Immune infiltration in human tumors: a prognostic factor that should not be ignored

  2010cited by this paper
• TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal Transition*

  2009cited by this paper
• TEAD mediates YAP-dependent gene induction and growth control.

  2008cited by this paper
• A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells.

  2008cited by this paper
• Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP*

  2008cited by this paper
• Mst2 and Lats Kinases Regulate Apoptotic Function of Yes Kinase-associated Protein (YAP)*

  2008cited by this paper
• Interleukin-7 receptor expression: intelligent design

  2007cited by this paper
• Taming the Hippo: Raf-1 Controls Apoptosis by Suppressing MST2/Hippo

  2005cited by this paper
• hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts.

  2003cited by this paper
• The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis.

  2003cited by this paper
• Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway

  2003cited by this paper

• Hippo signaling as a therapeutic switch for T cell functions and tumor immunity.

  2026cites this paper
• Multidimensional Regulatory Mechanisms of Extracellular Matrix Stiffness in Breast Cancer and Its Prospects for Clinical Translation

  2026cites this paper
• Beyond the chaos: How architecture structures tumour biology.

  2026cites this paper
• SLC5A11 Mediates Metformin-Induced PD-L1 Suppression to Enhance Cancer Immunotherapy through AMPK-IRF1 Signaling.

  2026cites this paper
• Do Metastatic Cells Arise from PD-L1+ Cell Niches in Gastric Adenocarcinoma?

  2026cites this paper
• Targeting the hippo pathway as a potential regulator of immune checkpoints in cancer immunotherapy.

  2025cites this paper
• Kinome-Wide Screening Identifies FAK as a Novel Post-Translational Regulator of PD-L1 Stability and Immune Evasion in Triple-Negative Breast Cancer

  2025cites this paper
• Activated Hippo Pathway is Associated with a Worse Response to Trastuzumab and Worse Survival in HER2-Positive Breast Cancer

  2025cites this paper
• Research advances in the study of traditional Chinese medicine formula granules on signaling pathway-mediated disease mechanisms

  2025cites this paper
• SLAMF1 expression in breast cancer cells delays tumor growth in vivo

  2025cites this paper
• Atypical Hippo signaling network: uncovering novel insights into head and neck cancer biology and advancements in precision intervention

  2025cites this paper
• PARP1-mediated PARylation of TEAD4 stabilizes the YAP1-TEAD4 complex and promotes growth and immune evasion in breast cancer cells.

  2025cites this paper
• Dysadherin/YAP axis fuels stem plasticity and immune escape in liver cancer

  2025cites this paper
• Correlation analysis of DLG5 and PD-L1 expression in triple-negative breast cancer

  2025cites this paper
• Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer

  2025cites this paper
• TEAD inhibition alters the lung immune microenvironment and attenuates metastasis

  2025cites this paper
• Loss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression

  2025cites this paper
• Hippo signaling pathway in cervical cancer: insights into mechanisms and therapeutic potential

  2025cites this paper
• Epithelioid Hemangioendothelioma: Treatment Landscape and Innovations for an Ultra-Rare Sarcoma

  2025cites this paper
• Integrating tumor macroenvironment, microenvironment and mechanobiology with organoid and organ-on-a-chip models for lung cancer immunotherapy.

  2025cites this paper
• Nucleus-translocated glucokinase functions as a protein kinase to phosphorylate TAZ and promote tumour growth

  2025cites this paper
• LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma

  2025cites this paper
• Molecular basis and therapeutic implications of binary YAPOn/YAPOff cancer classes

  2025cites this paper
• Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer

  2025cites this paper
• Current and emerging concepts for systemic treatment of metastatic colorectal cancer

  2025cites this paper
• Mechanical mechanics-reclaiming a new battlefield for chronic liver disease

  2025cites this paper
• Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models

  2025cites this paper
• YAP and TEAD Are Transcriptional Regulators of Neuroendocrine Differentiation and Growth in Carcinoid Cells

  2025cites this paper
• Gastrointestinal cancer: molecular pathogenesis and targeted therapy

  2025cites this paper
• TET2 orchestrates YAP signaling to potentiate targetable vulnerability in hepatocellular carcinoma

  2025cites this paper
• TEAD4-siRNA as an Emerging Drug for the Treatment of Gastric Cancer

  2025cites this paper
• Cancer chemoprevention: signaling pathways and strategic approaches

  2025cites this paper
• Proteasome stress activates YAP/TAZ through the RAP2-MAP4Ks-LATS1/2 pathway and its therapeutic implications in solid tumors.

  2025cites this paper
• Determinants of Response to Immune Checkpoint Blockade in Pleural Mesothelioma: Molecular, Immunological, and Clinical Perspectives

  2025cites this paper
• An EBNA1-YAP signaling axis drives immune escape through CD276 in EBV-associated gastric cancer

  2025cites this paper
• Epithelial-Mesenchymal Transition Activates YAP to Drive Malignant Progression and Immune Evasion

  2025cites this paper
• The interplay between tissue‐resident microbiome and host proteins by integrated multi‐omics during progression of colorectal adenoma to carcinoma

  2025cites this paper
• HDAC inhibitors modulate Hippo pathway signaling in hormone positive breast cancer

  2025cites this paper
• YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer

  2025cites this paper
• Expression of YAP1 and TAZ in Melanoma-, Bronchial- and Breast Carcinoma Brain Metastasis: Primary vs. Relapsed Tumors

  2025cites this paper
• Alexidine is a TAZ-specific small-molecule inhibitor that suppresses breast cancer invasion and metastasis

  2025cites this paper
• Loss of CFIm activates YAP/TAZ and connects mRNA cleavage and polyadenylation inhibition to BRCAness

  2025cites this paper
• The multifaceted role of YAP in the tumor microenvironment and its therapeutic implications in cancer

  2025influential citation
• Recent Advances in Combination Therapy of YAP Inhibitors with Physical Anti-Cancer Strategies

  2025cites this paper
• Natural compounds targeting YAP/TAZ axis in cancer: Current state of art and challenges.

  2024cites this paper
• HSP90 Inhibitor AUY922 Suppresses Tumor Growth and Modulates Immune Response through YAP-TEAD Pathway Inhibition in Gastric Cancer.

  2024cites this paper
• Identification of PTPN12 Phosphatase as a Novel Negative Regulator of Hippo Pathway Effectors YAP/TAZ in Breast Cancer

  2024cites this paper
• Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma

  2024cites this paper
• FOXA1 enhances antitumor immunity via repressing interferon-induced PD-L1 expression in nasopharyngeal carcinoma

  2024cites this paper
• Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers

  2024cites this paper
• Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.

  2024cites this paper
• Nuclear localization of YAP is associated with tumor progression in cutaneous melanoma.

  2024cites this paper
• TAZ deficiency impairs the autophagy-lysosomal pathway through NRF2 dysregulation and lysosomal dysfunction

  2024cites this paper
• The molecular crosstalk of the hippo cascade in breast cancer: A potential central susceptibility.

  2024cites this paper
• ZMIZ2 facilitates hepatocellular carcinoma progression via LEF1 mediated activation of Wnt/β-catenin pathway

  2024cites this paper
• Role of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer

  2024cites this paper
• From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer

  2024cites this paper
• Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer

  2024cites this paper
• Statin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Cancer.

  2024cites this paper
• The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy

  2024cites this paper
• The role of C1orf50 in breast cancer progression and prognosis

  2024cites this paper
• Advances towards potential cancer therapeutics targeting Hippo signaling.

  2024cites this paper
• Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?

  2024cites this paper
• Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancer

  2024cites this paper
• Regulation of Tumor Microenvironment through YAP/TAZ under Tumor Hypoxia

  2024cites this paper
• Identification and Validation of TEAD Family’s Prognostic Effects and Immune Microenvironment Regulations in Glioma

  2024cites this paper
• STC1 competitively binding βPIX enhances melanoma progression via YAP nuclear translocation and M2 macrophage recruitment through the YAP/CCL2/VEGFA/AKT feedback loop.

  2024cites this paper
• PKP2 induced by YAP/TEAD4 promotes malignant progression of gastric cancer

  2024cites this paper
• Integrating transcriptomics, metabolomics, and network pharmacology to investigate multi-target effects of sporoderm-broken spores of Ganoderma lucidum on improving HFD-induced diabetic nephropathy rats

  2024cites this paper
• Targeting Nuclear Receptor Coactivator SRC‐1 Prevents Colorectal Cancer Immune Escape by Reducing Transcription and Protein Stability of PD‐L1

  2024cites this paper
• YAP, TAZ, and Hippo-Dysregulating Fusion Proteins in Cancer

  2024cites this paper
• Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms

  2023cites this paper
• Integrating single-cell and bulk RNA sequencing to develop a cancer-associated fibroblast-related signature for immune infiltration prediction and prognosis in lung adenocarcinoma

  2023cites this paper
• The Regulation and Double-Edged Roles of the Deubiquitinase OTUD5

  2023cites this paper
• Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

  2023cites this paper
• The Hippo signaling pathway: from multiple signals to the hallmarks of cancers

  2023cites this paper
• A therapeutically targetable TAZ-TEAD2 pathway drives the growth of hepatocellular carcinoma via ANLN and KIF23.

  2023cites this paper
• Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors

  2023cites this paper
• Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC)

  2023cites this paper
• The oncogenic roles and clinical implications of YAP/TAZ in breast cancer

  2023cites this paper
• Optimization of cancer immunotherapy on the basis of programmed death ligand‐1 distribution and function

  2023cites this paper
• Ezrin regulates the progression of NSCLC by YAP and PD-L1

  2023cites this paper
• Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer

  2023cites this paper
• YTHDF2-mediated circYAP1 drives immune escape and cancer progression through activating YAP1/TCF4-PD-L1 axis

  2023cites this paper
• Deciphering the role of Hippo pathway in lung cancer.

  2023cites this paper
• Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance1.

  2023cites this paper
• Bioinformatics analysis and experimental validation identified HMGA2/microRNA-200c-3p/LSAMP/Wnt axis as an immunological factor of patients with colorectal cancer.

  2023cites this paper
• Genome-Wide Characterization of TAZ Binding Sites in Mammary Epithelial Cells

  2023cites this paper
• Development of a New HiBiT Biosensor Monitoring Stability of YAP/TAZ Proteins in Cells

  2023cites this paper
• TAZ facilitates breast tumor growth by promoting an immune‐suppressive tumor microenvironment

  2023cites this paper
• Multi-Functional Regulation by YAP/TAZ Signaling Networks in Tumor Progression and Metastasis

  2023cites this paper
• Clinicopathological Significance of DUB3 Expression in Non-small Cell Lung Cancer and Relationship Between DUB3 Expression and LATS1 Expression

  2023cites this paper
• PD-L1-mediated immune evasion in triple-negative breast cancer is linked to the loss of ZNF652.

  2023cites this paper
• Matrix stiffness-driven cancer progression and the targeted therapeutic strategy

  2023cites this paper
• Control of stem cell renewal and fate by YAP and TAZ

  2023cites this paper
• Expression and in vitro function of anti-PD-L1 human antibody expressed in plant

  2023cites this paper
• Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer

  2023cites this paper
• Searching for Novel Biomarkers in Thymic Epithelial Tumors: Immunohistochemical Evaluation of Hippo Pathway Components in a Cohort of Thymic Epithelial Tumors

  2023cites this paper
• YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer

  2023cites this paper
• The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells

  2023cites this paper